Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1450 of 1475 entries
View as:

ATV/Ritonavir Nevirapine Interaction (USPAC)

Phase: N/A Priority: Normal
NCT ID: NCT00162149 Org: User:
Start: 10/31/05 End: 07/31/06 Due: 07/31/07

A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Phase: N/A Priority: Normal
NCT ID: NCT00002369 Org: User:
Start: - End: - Due: -

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01471717 Org: User:
Start: 10/31/11 End: 11/30/11 Due: 11/30/12

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06715683 Org: User:
Start: 12/12/24 End: 03/16/25 Due: 03/16/26

A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread

Phase: N/A Priority: Normal
NCT ID: NCT03161145 Org: User:
Start: 12/09/16 End: 08/31/17 Due: 08/31/18

Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine

Phase: N/A Priority: Normal
NCT ID: NCT00002035 Org: User:
Start: - End: 04/30/92 Due: 04/30/93

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Phase: N/A Priority: Normal
NCT ID: NCT04817007 Org: User:
Start: 03/23/21 End: 05/31/26 Due: 05/31/27

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

Phase: N/A Priority: Normal
NCT ID: NCT00457002 Org: User:
Start: 06/30/07 End: 05/31/11 Due: 05/31/12

A Study of Nivolumab in Patients With Head and Neck Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT04050761 Org: User:
Start: 06/26/19 End: 09/08/24 Due: 09/08/25

Effect of BMS-986165 on the Blood Levels of Metformin

Phase: N/A Priority: Normal
NCT ID: NCT04671953 Org: User:
Start: 12/18/20 End: 03/30/21 Due: 03/30/22

Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

Phase: N/A Priority: Normal
NCT ID: NCT01707394 Org: User:
Start: 01/10/13 End: 06/30/20 Due: 06/30/21

A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT00277225 Org: User:
Start: 11/30/95 End: 06/30/96 Due: 06/30/97

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05244070 Org: User:
Start: 09/14/22 End: 05/04/23 Due: 05/04/24

Abatacept Pregnancy Exposure Registry

Phase: N/A Priority: Normal
NCT ID: NCT01087125 Org: User:
Start: 09/01/06 End: 12/31/19 Due: 12/31/20

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Phase: N/A Priority: Normal
NCT ID: NCT04857034 Org: User:
Start: 07/12/21 End: 02/28/28 Due: 02/28/29

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Phase: N/A Priority: Normal
NCT ID: NCT02060188 Org: User:
Start: 03/12/14 End: 10/22/24 Due: 10/22/25

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04209114 Org: User:
Start: 02/05/20 End: 06/07/23 Due: 06/07/24

A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435

Phase: N/A Priority: Normal
NCT ID: NCT05686096 Org: User:
Start: 01/16/23 End: 04/08/23 Due: 04/08/24

Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

Phase: N/A Priority: Normal
NCT ID: NCT01797848 Org: User:
Start: 06/30/14 End: 11/30/16 Due: 11/30/17

An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04008992 Org: User:
Start: 06/18/19 End: 01/04/21 Due: 01/04/22

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00320255 Org: User:
Start: 06/30/06 End: 01/31/09 Due: 01/31/10

A Phase 1 Drug-drug Interaction Study in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02227173 Org: User:
Start: 09/30/14 End: 11/30/14 Due: 11/30/15

A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00460954 Org: User:
Start: 06/30/07 End: 08/31/07 Due: 08/31/08

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Phase: N/A Priority: Normal
NCT ID: NCT00101816 Org: User:
Start: 12/31/04 End: 03/31/08 Due: 03/31/09

Single Ascending Dose (BMS-813160) Study

Phase: N/A Priority: Normal
NCT ID: NCT01049165 Org: User:
Start: 02/28/10 End: 11/30/10 Due: 11/30/11